Haemonetics Corp (NYSE:HAE)

$ 83.51 -1.75 (-2.05%) Market Cap: 4.19 Bil Enterprise Value: 5.21 Bil PE Ratio: 34.65 PB Ratio: 4.79 GF Score: 76/100

Q2 2025 Haemonetics Corp Earnings Call Transcript
Nov 07, 2024

$86.53 (+10.71%)

Earnings
Q1 2025 Haemonetics Corp Earnings Call Transcript
Aug 08, 2024

$76.43 (-10.84%)

Earnings
Haemonetics Corp at Citi Unplugged Medtech and Life Sciences Access Day Transcript
Feb 29, 2024
Q3 2024 Haemonetics Corp Earnings Call Transcript
Feb 08, 2024

$78.11 (+1.30%)

Earnings
Haemonetics Corp at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q2 2024 Haemonetics Corp Earnings Call Transcript
Nov 02, 2023

$85.46 (-1.08%)

Earnings
Q1 2024 Haemonetics Corp Earnings Call Transcript
Aug 08, 2023

$89.94 (+1.46%)

Earnings
Q4 2023 Haemonetics Corp Earnings Call Transcript
May 11, 2023

$85.84 (+3.30%)

Earnings
Q3 2023 Haemonetics Corp Earnings Call Transcript
Feb 07, 2023

$82.57 (-5.91%)

Earnings
Haemonetics Corp at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q2 2023 Haemonetics Corp Earnings Call Transcript
Nov 07, 2022

$83.57 (+3.61%)

Earnings
Haemonetics Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Q1 2023 Haemonetics Corp Earnings Call Transcript
Aug 10, 2022

$73.6 (+8.89%)

Earnings
Haemonetics Corp Investor Day Transcript
Jun 29, 2022
Q4 2022 Haemonetics Corp Earnings Call Transcript
May 10, 2022

$54.38 (+10.37%)

Earnings
Haemonetics Corp at Raymond James Institutional Investors Conference Transcript
Mar 07, 2022
Q3 2022 Haemonetics Corp Earnings Call Transcript
Feb 08, 2022

$54.56 (+16.16%)

Earnings
Q2 2022 Haemonetics Corp Earnings Call Transcript
Nov 09, 2021

$60.2 (-15.37%)

Earnings
Haemonetics Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q1 2022 Haemonetics Corp Earnings Call Transcript
Aug 11, 2021

$61.97 (+7.29%)

Earnings
Q4 2021 Haemonetics Corp Earnings Call Transcript
May 13, 2021

$51.81 (-13.40%)

Earnings
Haemonetics Corp at Jefferies Virtual Plasma Summit Transcript
Mar 11, 2021
Q3 2021 Haemonetics Corp Earnings Call Transcript
Feb 02, 2021

$129.93 (+12.98%)

Earnings
Haemonetics Corp Acquisition Of Cardiva Medical Inc Conference Call Transcript
Jan 20, 2021
Q2 2021 Haemonetics Corp Earnings Call Transcript
Nov 04, 2020

$95.3 (-6.75%)

Earnings
Haemonetics Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
Q1 2021 Haemonetics Corp Earnings Call Transcript
Aug 04, 2020

$76.38 (-12.41%)

Earnings
Q4 2020 Haemonetics Corp Earnings Call Transcript
May 05, 2020

$106.38 (-3.34%)

Earnings
Q3 2020 Haemonetics Corp Earnings Call Transcript
Feb 04, 2020

$121.82 (+9.36%)

Earnings
Q2 2020 Haemonetics Corp Earnings Call Transcript
Nov 01, 2019

$129.46 (+7.23%)

Earnings
Haemonetics Corp at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Q1 2020 Haemonetics Corp Earnings Call Transcript
Aug 06, 2019

$131.24 (+12.02%)

Earnings
Q4 2019 Haemonetics Corp Earnings Call Transcript
May 07, 2019

$97.99 (+4.40%)

Earnings

Q1 2025 Haemonetics Corp Earnings Call Transcript

Aug 08, 2024 / 12:00PM GMT

Release Date Price: $76.43 (-10.84%)

Transcript 10-Q8-K

Operator

Thank you for standing by, and welcome to Haemonetics Corporation's first quarter fiscal year 2025 earnings conference call. (Operator Instructions)

I would now like to hand the call over to Olga Guyette, Vice President, Investor Relations and Treasury. Please go ahead.

Olga Guyette

Haemonetics Corp - Vice President, Investor Relations and Treasury

Good morning, everyone. Thank you for joining us for Haemonetics' first quarter fiscal year 2025 conference call and webcast. I'm joined today by Chris Simon, our CEO; and James C. DâArecca, our CFO. This morning, we posted our first quarter fiscal year 2025 results to our Investor Relations website, along with our fiscal '25 guidance.

Before we begin, a quick reminder that all revenue growth rates discussed today are organic unless specified otherwise and exclude the impact of currency fluctuation and acquisitions.

Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from offsets due to the acquisition closing date being in December 2023. We'll also

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.